Chamber and committees

The University of Strathclyde has been commissioned to undertake critical evaluation of early adopter sites to inform wider roll-out, ensuring learnings from the first three Services are embedded, working towards equitable access across NHS Scotland, as set out in the NHS Recovery Plan.

In the meantime, officials are working with Boards to open additional early adopter sites.

Recruitment will be undertaken by the host Board, and will be dependent on their locally agreed pathway and resourcing requirements.

£10 million of funding has been directed to support Cancer Waiting Times improvements in our NHS across 2022-23. Significant funds are going towards up-skilling nurses and investing in diagnostic tests to support extended working days/weekend working to increase capacity.

Meanwhile, work is underway to develop Scotland’s new cancer strategy, expected to publish Spring 2023. A recent public consultation received over 250 responses, including from blood cancer charities. A series of workshops are planned throughout September to help gain further insight and hear directly from those with lived experience to inform the focus of this strategy.

Throughout the pandemic, a UK-wide approach to the procurement of therapeutics has been vital to allow the UK to have the buying power to secure significant numbers of therapeutics in a competitive global market. This approach has ensured patients across the UK have had equal access to safe and effective medicines.

Evusheld ® was developed and tested before the emergence of the Omicron variant, and the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) conditional marketing authorisation outlined some remaining questions, including how effective Evusheld ® is against Omicron and the duration of its effect against current circulating variants. As a result, there is currently no established supply arrangement for Evusheld ® in the UK. The UK Health Security Agency (UKHSA) is carrying out further testing on the effectiveness of Evusheld ® against the Omicron variants which involve “live virus” tests taking place in the lab (“in vitro”). These tests are important because they provide certainty of the effectiveness of Evusheld ® against circulating variants and avoid the risk of introducing new variants through viral mutations.

The Scottish Government continues to closely monitor the outcome of further research to ensure that any decisions to make Evusheld ® available to patients in Scotland in the future are based on the best available evidence.

The Scottish Stroke Improvement Programme (SSIP) Lead conducts a review process and meets with all NHS boards to understand the provision of stroke services and create a local action plan to improve performance where needed.

We recognise that the Scottish Stroke Care Standards are challenging for the service and expect Stroke Managed Clinical Networks and Health Boards to work together to drive forward quality improvement programmes of work to achieve these.

I refer the member to the answer to question S6W-10404 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

I refer the member to the answer to question S6W-10433 on 20 September 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

The Scottish Stroke Improvement Programme report, published on 28 June, includes data from the Scottish Stroke Care Audit (SSCA). The SSCA measures quality of care of stroke services in each acute hospital, grouped by NHS board against the Scottish Stroke Care Standards.

I refer the member to the answer to question S6W-09978 on 24 August 2022. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.

Three Rapid Cancer Diagnostic Services (RCDS), formerly known as Early Cancer Diagnostic Centres (ECDC), have been established in NHS Scotland, and we are committed to ensuring equitable access across the country.

RCDS’s provide primary care with a new referral route for patients with non-specific symptoms suspicious of cancer (i.e. weight loss, fatigue, nausea), which can often be a sign of blood cancer. The Clinical Leads for two of the Services are Haematologists, reflecting the role that this new model can play in diagnosing blood cancers earlier.

Our NHS Recovery Plan commits to providing greater public awareness of signs and symptoms of cancer, with a new national campaign in development and website being re-designed.

The Scottish Government will continue to work closely with primary care clinicians, including the Scottish Primary Care Cancer Group, to identify possible symptoms as early as possible and support appropriate referral via the Scottish Referral Guidelines for Suspected Cancer.

The Scottish Government is committed to the recruitment of a minimum of 1,500 additional staff to support the operation of Scotland’s National Treatment Centres (NTCs) and is supporting a range of activity to achieve this.

The recruitment data we collate is management information and not suitable for publication. NTC Recruitment is the responsibility of each NHS Board. It is therefore for NHS Golden Jubilee to provide detail regarding their recruitment.